Dublin-based Trinity Biotech Plc shares jumped 6% premarket Monday, after the company said it has received approval from the World Health Organization for its HIV screening product, TrinScreen. The company’s Uni-Gold HIV product has served as the main confirmatory test for the detection of HIV in Africa for many years. The new product is expected to have an estimated market size of more than $150 million. “TrinScreen(TM) HIV is a rapid test providing results in less than 12 minutes from a finger stick drop of blood and the test has demonstrated excellent performance in both an independent evaluation sponsored by the WHO and in a multi-centre clinical evaluation conducted in Africa in 2020 by the Company,” Trinity said in a statement.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
